PRMT5 inhibitor as well as preparation method and pharmaceutical application thereof
Patent Information
- Application Number
- CN202380033442.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-26
- Filing Date
- 2023-06-26
- Publication Date
- 2024-11-22
AI Technical Summary
Current technologies struggle to target PRMT5 in MTAP-deficient tumor cells while avoiding side effects in normal cells, resulting in a limited therapeutic window for PRMT5 inhibitors.
A PRMT5 inhibitor has been developed, characterized by a compound of formula (I), which selectively targets PRMT5 in the MTA-bound state, accumulates only in MTAP-deficient tumor cells, and avoids action in normal cells with intact MTAP.
This study achieved effective inhibition of PRMT5 in MTAP-deficient tumor cells, reduced side effects on normal cells, and provided a better therapeutic window.
Smart Images

Figure CN119013274A_ABST
Abstract
Description
A PRMT5 inhibitor, its preparation method and pharmaceutical application Technical Field
[0001] The present invention belongs to the field of drug synthesis, and specifically relates to a PRMT5 inhibitor, a preparation method thereof, and pharmaceutical applications thereof. Background Art
[0002] Epigenetic gene regulation is an important biological regulatory mechanism for protein synthesis and cell differentiation, and plays an important role in many human diseases.
[0003] Epigenetic regulation involves the manipulation of inherited genetic material without altering its nucleic acid sequence. Typically, epigenetic regulation is achieved by selective and reversible modifications (e.g., methylation) of DNA and proteins (e.g., histones) to control the transition between transcriptionally active and inactive states of chromatin conformation. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., PRMT5), many of which are associated with specific genetic alterations in numerous human disease-causing genes. PRMT5 plays a crucial role in numerous diseases, including cancer, metabolic disorders, and hematologic diseases.
[0004] Homozygous deletion of tumor suppressor genes is a tumor driver and often results in the loss of nearby passenger genes. Loss of these passenger genes confers tumor cell-specific vulnerabilities that can be targeted with targeted therapies. Homozygous deletion of chromosome 9p21, encompassing the well-known tumor suppressor gene CDKN2A, occurs in 15% of tumors and often includes loss of the passenger gene MTAP. MTAP is a key enzyme in the methionine and adenine recycling pathway. Loss of MTAP leads to the accumulation of its substrate, MTA. MTA shares structural similarities with S-adenosylmethionine (SAM), the methyl group donor for the type II methyltransferase PRMT5. Elevated MTA levels due to MTAP loss selectively compete with SAM for PRMT5 binding, rendering the methyltransferase inactive and susceptible to PRMT5 inhibition. A variety of genome-wide shRNA screens across a wide range of tumor cell lines have demonstrated a correlation between MTAP deficiency and cell line dependence on PRMT5, placing the impact of this metabolic vulnerability in the spotlight. However, as PRMT5 is a critical gene for cells, studies using conditional knockout or siRNA knockdown of PRMT5 have suggested that inhibiting PRMT5 in normal tissues can have significant side effects (e.g., cytopenias, infertility, skeletal muscle loss, cardiac hypertrophy, etc.). Therefore, new strategies are needed to exploit and explore this metabolic vulnerability, selectively targeting PRMT5 in MTAP-deficient tumors while avoiding its effects in normal tissues (MTAP wild-type).
[0005] Small molecule inhibitors targeting PRMT5 that collaborate with MTA can selectively target only PRMT5 in the MTA-bound state, and this PRMT5 is only enriched in tumor cells that lack MTAP. Therefore, in normal cells with intact MTAP, when MTA levels are very low, PRMT5 will not be targeted, thus providing a better therapeutic window.
[0006] Summary of the Invention
[0007] The present invention aims to provide a PRMT5 inhibitor, its preparation method, and pharmaceutical applications. The compounds of the present invention have a strong inhibitory effect on PRMT5 and can be widely used to prepare drugs for treating and / or preventing PRMT5-mediated diseases, thereby potentially leading to the development of a new generation of PRMT5 inhibitors.
[0008] The first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0009] wherein X1 is CR6 or N; X2 is CR7 or N; X3 is CR8 or N;
[0010] Ring A is C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0011] Ring B is selected from a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, wherein the nitrogen atom is connected to the carbonyl group, wherein
[0012] 1) When ring B is selected from a 4-membered nitrogen-containing heterocyclic group, an 8-10-membered nitrogen-containing heterocyclic group or an 8-10-membered nitrogen-containing heteroaryl group,
[0013] Ring C is C 3-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-12 Cycloalkyl or 4-12 membered heterocyclic group is optionally fused to C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 Aryl or 5-10 membered heteroaryl is optionally fused to C 3-12 Cycloalkyl or 4-12 membered heterocyclic group;
[0014] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0015] 2) When ring B is selected from a 5-7 membered nitrogen-containing heterocyclic group or a 5-7 membered nitrogen-containing heteroaryl group,
[0016] Ring C and -(R1) m Together they form: in,
[0017] a) When ring C and -(R1) m Together When Y1 and Y2 are each independently CR1 or N, Y3 is O, S or NR1', and Y4 and Y5 are each independently CR1" or N;
[0018] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0019] R1' is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0020] Each R1" is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0021] b) When ring C and -(R1) m Together When Y6, Y7, Y8 and Y9 are each independently CR1 or N, and at least one is selected from CR1, wherein at least one R1 is -C 0-8 Alkyl-NR 14 R 15 or -OC 1-4 Alkyl-NR 14 R 15 , each other R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0022] Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12)-C(O)R 11 , or, when p ≥ 2, wherein two R2 together with the moiety to which they are directly attached form a C(O);
[0023] R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyl and -NR 12 R 13 substituted by a substituent;
[0024] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0025] R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 ;
[0026] Each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;
[0027] Each R 10 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;
[0028] Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;
[0029] Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent, or
[0030] R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent;
[0031] R 14 and R 15 are each independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2 and -C 0-8 Alkyl-C(O)NR 12 R 13 , or, R 14 and R 15 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0032] Each r is independently 0, 1, or 2;
[0033] m is selected from 0, 1, 2, 3, 4 or 5;
[0034] n is selected from 0, 1, 2, 3, 4 or 5; and
[0035] p is selected from 0, 1, 2, 3, 4 or 5.
[0036] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R3 and R4 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 12 R 13 substituted by a substituent; wherein R 12 and R 13 As described for the compound of formula (I).
[0037] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R3 and R4 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups.
[0038] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R6, R7 and R8 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0039] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R6, R7 and R8 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11)2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ;
[0040] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0041] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 14 and R 15 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2 and -C 0-4 Alkyl-C(O)NR 12 R 13 , or, R 14 and R 15 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4Alkyl-C(O)OR 10 、 -C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 wherein R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0042] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 14 and R 15 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -C(O)OR 10 、-C(O)SR 10 、-C(O)R 11 、-P(O)(R 11 )2 and -C(O)NR 12 R 13 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0043] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 wherein R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0044] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 wherein R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0045] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R2 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 , or, when p≥2, two R2 and their directly connected parts together form a C(O); wherein R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0046] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, ring B is selected from a 4-membered nitrogen-containing heterocyclic group;
[0047] Ring C is C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 3-6 Cycloalkyl or 4-8 membered heterocyclic group is optionally fused to C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is optionally fused to C 3-6 Cycloalkyl or 4-8 membered heterocyclic group;
[0048] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0049] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0050] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, ring B is selected from an 8-10 membered nitrogen-containing heterocyclic group;
[0051] Ring C is C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 3-6 Cycloalkyl or 4-8 membered heterocyclic group is optionally fused to C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is optionally fused to C 3-6 Cycloalkyl or 4-8 membered heterocyclic group;
[0052] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 wherein R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0053] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Ring B is selected from a 5-7 membered nitrogen-containing heterocyclic group, Ring C and -(R1) m Together wherein Y1 and Y2 are each independently CR1 or N, Y3 is O, S or NR1′, and Y4 and Y5 are each independently CR1″ or N;
[0054] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0055] R1' is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11)2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0056] Each R1" is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0057] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0058] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Ring B is selected from a 5-7 membered nitrogen-containing heterocyclic group, Ring C and -(R1) m Together wherein Y6, Y7, Y8 and Y9 are each independently CR1 or N, and at least one is CR1, wherein at least one R1 is -C 0-4 Alkyl-NR 14 R 15 or -OC 1-4 Alkyl-NR 14 R 15 , each other R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent;
[0059] Among them, R9, R 10 、R 11 、R 12 、R 13 、R 14 、R 15 and r are as described for the compound of formula (I).
[0060] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;
[0061] Each R 10 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;
[0062] Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent;
[0063] Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 substituted with an alkanoyl substituent, or
[0064] R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-8 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.
[0065] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Ring A and the part directly connected thereto together form the following structure:
[0066] Wherein, X1 is CR6 or N; X2 is CR7 or N;
[0067] Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0068] Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0069] Each R 5care each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、 -C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0070] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;
[0071] Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;
[0072] Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;
[0073] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0074] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following compound structure of formula (II):
[0075] wherein Y1 and Y2 are each independently CR1 or N, and Y3 is O, S or NR1′;
[0076] Ring A is C 4-8 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl;
[0077] Ring B and -(R2) p Together they form the following structure:
[0078] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0079] R1' is selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0080] Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ;
[0081] R2' is selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups;
[0082] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ;
[0083] R6 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, hydroxyl and -NR 12 R 13 ;
[0084] Among them, R9, R 10 、R 11 、R 12 、R 13 , n, p and r are as described for the compound of formula (I).
[0085] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, Ring A and the part directly connected thereto together form the following structure:
[0086] Wherein, X1 is CR6 or N; X2 is CH or N;
[0087] Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0088] Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0089] Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent;
[0090] Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ;
[0091] Among them, R9, R 10 、R 11 、R 12 、R 13 and r are as described for the compound of formula (I).
[0092] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following structure of the compound of formula (III1) or formula (III2):
[0093] Wherein, the compound of formula (III1) or formula (III2) has the following structure: The structure is
[0094] Ring A and its directly connected parts together form the following structure:
[0095] R is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, dimethylamino-substituted methyl, dimethylamino-substituted ethyl, dimethylaminoethoxy, cyclopropyl, cyclobutyl, piperidinyl, piperazinyl, morpholinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, methyl-substituted piperazinyl, cyclopropyl-substituted piperazine, and tetrahydropyranyl;
[0096] R1' is selected from hydrogen, deuterium, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, dimethylamino-substituted methyl, dimethylamino-substituted ethyl, cyclopropyl, cyclobutyl, piperidinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, and tetrahydropyranyl;
[0097] Each R2 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium and cyclopropyl;
[0098] Each R 5a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, cyclopropyl, -SF5 and hydroxyl;
[0099] Each R 5b are each independently selected from hydrogen, deuterium, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl and cyclopropyl;
[0100] Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, cyclopropyl, -SF5 and hydroxyl;
[0101] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, cyclopropyl, -SF5 and hydroxyl;
[0102] p is selected from 0, 1 or 2.
[0103] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (III1) or formula (III2) has The structure is
[0104] Ring A and its directly connected parts together form the following structure:
[0105] wherein R1 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino-substituted ethyl, dimethylamino-substituted ethoxy, cyclopropyl, piperidinyl, piperazinyl, morpholinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, methyl-substituted piperazinyl, cyclopropyl-substituted piperazine, and tetrahydropyranyl;
[0106] Each R2 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0107] Each R 5a are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0108] Each R 5b are each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl;
[0109] Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0110] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl.
[0111] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) has the following structure of formula (IV1), formula (IV2), formula (IV3) or formula (IV4):
[0112] in,
[0113] each R1 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino-substituted ethyl, dimethylamino-substituted ethoxy, cyclopropyl, piperidinyl, piperazinyl, morpholinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, methyl-substituted piperazinyl, cyclopropyl-substituted piperazinyl, and tetrahydropyranyl;
[0114] Each R 2a are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0115] Each R 2b are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0116] Each R 5aare each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0117] Each R 5b are each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl;
[0118] Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0119] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl.
[0120] As the most preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof include but are not limited to the following compounds:
[0121] In a second aspect, the present invention provides a method for preparing a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, comprising the steps of reacting a compound of formula (Ia) with a compound of formula (Ib) to produce a compound of formula (I), as shown in the following reaction formula:
[0122] wherein X is hydroxy or halogen; and ring A, ring B, ring C, R1, R2, R3, R4, R5, X1, X2, X3, m, n and p are as defined for the compound of formula (I).
[0123] The third aspect of the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0124] The fourth aspect of the present invention provides the use of a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating MATP-related tumors.
[0125] As a further preferred embodiment, the tumor is selected from the group consisting of cell tumors, lymphomas, leukemias, osteomas, malignant teratomas, intraepithelial carcinomas, adenomas, fibromas, melanomas, fallopian tube cancer, bladder cancer, teratomas, embryonal carcinomas, choriocarcinomas, lipomas, liver cancer, bile duct cancer, lung cancer, gastric cancer, hemangiomas, gallbladder cancer, ampullary cancer, malignant melanomas, nevi, dysplastic nevi, myeloproliferative diseases, Hodgkin's disease, chordomas, myxomas, rhabdomyomas, leiomyomas, hamartomas, mesotheliomas, insulinomas, glucagonomas, gastrinomas, carcinoid tumors, viper tumors, granulomas, xanthomas, osteitis deformans, ependymomas, neurilemmomas, congenital tumors, meningiomas, gliomas, skin cancers, head and neck cancers, and sarcomas.
[0126] As a further preferred embodiment, the cell tumor is selected from granulosa-thecoma cell tumor, Sertoli cell tumor, germ cell tumor, Wilms tumor, seminoma, hepatoblastoma, malignant fibrous histiocytoma, chondroblastoma, giant cell tumor, astrocytoma, medulloblastoma, glioblastoma multiforme, oligodendroglioma, retinoblastoma, squamous cell carcinoma, clear cell carcinoma, transitional cell carcinoma, interstitial cell carcinoma and basal cell carcinoma;
[0127] The lymphoma is selected from malignant lymphoma and non-Hodgkin's lymphoma;
[0128] The leukemia is selected from acute and chronic myeloid leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia;
[0129] The bone tumor is selected from osteochondroma, benign enchondroma, osteoid osteoma, enchondromatous hamartoma, multiple myeloma and skull tumor;
[0130] The adenoma is selected from the group consisting of fibroadenoma, adenomatoid tumor, hepatocellular adenoma, bronchial adenoma, tubular adenoma, villous adenoma, breast cancer, pancreatic cancer, endometrial adenocarcinoma, prostate cancer, ductal adenocarcinoma and colorectal adenocarcinoma;
[0131] The fibroma is selected from the group consisting of fibroma, chondromyxofibroma, neurofibroma and spinal neurofibroma;
[0132] The myeloproliferative disease is selected from the group consisting of multiple myeloma and myelodysplastic syndrome;
[0133] The lung cancer is selected from bronchogenic carcinoma and alveolar carcinoma;
[0134] The sarcoma is selected from the group consisting of fibrosarcoma, botryoid sarcoma, angiosarcoma, Kaposi's sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, and meningeal sarcoma.
[0135] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, which are used as PRMT5 inhibitor drugs.
[0136] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating and / or preventing PRMT5-mediated diseases.
[0137] The present invention also relates to a method for treating and / or preventing a disease mediated by PRMT5, comprising administering a therapeutically effective amount of the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a patient in need thereof. DETAILED DESCRIPTION
[0138] After extensive and in-depth research, the inventors of this application have developed for the first time a PRMT5 inhibitor having the structure of Formula (I) below. This series of compounds can be widely used in the preparation of drugs for treating and / or preventing PRMT5-mediated diseases and is expected to be developed into a new generation of PRMT5 inhibitors. Based on this, the present invention was completed.
[0139] Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.
[0140] "Alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched alkyl group having 1 to 10, 1 to 6, or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl , 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or its various branched chain isomers, etc. “C 1-10 "Alkyl" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 10 carbon atoms. 1-4 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups containing 1 to 4 carbon atoms, "C 0-8"Alkyl" refers to straight chain alkyl and branched chain alkyl groups including 0 to 8 carbon atoms, "C 0-4 The term "alkyl" refers to straight-chain and branched-chain alkyl groups having 0 to 4 carbon atoms.
[0141] Alkyl groups may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0142] "Cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system. Cycloalkyl is divided into monocyclic cycloalkyl and polycyclic cycloalkyl, preferably a cycloalkyl containing 3 to 12, 3 to 8 or 3 to 6 carbon atoms, for example, "C3-12 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 12 carbon atoms, "C 4-8 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 8 carbon atoms, "C 3-8 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 8 carbon atoms, "C 3-6 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 6 carbon atoms, wherein:
[0143] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.
[0144] Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups. "Spiroalkyl" refers to a polycyclic group in which the rings share a carbon atom (called a spiro atom). These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Spiroalkyl groups are classified as monospiroalkyl, bispiroalkyl, or polyspiroalkyl groups based on the number of spiro atoms shared between the rings. Spiroalkyl groups include, but are not limited to:
[0145] "Fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cycloalkyl groups include, but are not limited to:
[0146] "Bridged cycloalkyl" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:
[0147] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.
[0148] "Cycloalkyl" or "carbocycle" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0149] "Heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, and one or more (preferably 1, 2, 3 or 4) ring atoms in the heterocyclyl are selected from N, O, N·O or S(O) r (wherein r is an integer of 0, 1, or 2), but excluding the ring portion of -OO-, -OS-, or -SS-, the remaining ring atoms are carbon. Preferably, the heterocyclyl group comprises 3 to 12, 3 to 8, or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 6 ring atoms, "3-8 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 8 ring atoms, "4-8 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 8 ring atoms, "4-10 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 10 ring atoms, "5-8 membered heterocyclyl" refers to a heterocyclyl group comprising 5 to 8 ring atoms, and "3-12 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 12 ring atoms.
[0150] Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl, and the like.
[0151] Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "Spiro heterocyclic group" refers to a polycyclic heterocyclic group in which the single rings share an atom (called a spiro atom), wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O). r (where r is an integer 0, 1, or 2) with the remaining ring atoms being carbon. These may contain one or more double bonds (preferably 1, 2, or 3), but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are classified as monospiro heterocyclic groups, dispiro heterocyclic groups, or polyspiro heterocyclic groups based on the number of spiro atoms shared between the rings. Spiro heterocyclic groups include, but are not limited to:
[0152] "Fused heterocyclyl" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with the other rings in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, fused heterocyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused heterocyclic groups include, but are not limited to:
[0153] "Bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, these may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, bridged heterocyclic groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged heterocyclic groups include, but are not limited to:
[0154] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:
[0155] "Heterocyclyl" or "heterocycle" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The substituent is substituted by the substituent.
[0156] "Aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group, a polycyclic (i.e., rings with adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably an all-carbon aromatic group containing 6-10 or 6-8 carbon atoms, for example, "C 6-10 "Aryl" refers to an all-carbon aromatic group containing 6-10 carbon atoms, including but not limited to phenyl and naphthyl. 6-8 "Aryl" refers to an all-carbon aromatic group containing 6-8 carbon atoms. The aromatic ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aromatic ring, including but not limited to:
[0157] "Aryl" or "aromatic ring" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0158] "Heteroaryl" or "heteroaromatic ring" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N·O and S(O)r (wherein r is an integer of 0, 1 or 2), preferably a heteroaromatic system containing 5-10, 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, and "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:
[0159] "Heteroaryl" or "heteroaromatic ring" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0160] "Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched alkenyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkenyl" refers to a straight or branched chain alkenyl containing 2 to 10 carbon atoms. 2-4 "Alkenyl" refers to a straight or branched chain alkenyl group containing 2 to 4 carbon atoms, including but not limited to ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc.
[0161] "Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12)-C(O)R 11 substituted by a substituent.
[0162] "Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkynyl" refers to a straight or branched chain alkynyl containing 2 to 10 carbon atoms. 2-4 "Alkynyl" refers to a straight or branched chain alkynyl containing 2-4 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc.
[0163] "Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0164] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above, for example, "C 1-10 "Alkoxy" refers to an alkyloxy group containing 1 to 10 carbon atoms. 1-4 "Alkoxy" refers to an alkyloxy group containing 1 to 4 carbon atoms. 1-2 The term "alkoxy" refers to an alkyloxy group containing 1 to 2 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.
[0165] "Alkoxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0166] "Cycloalkoxy" or "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above, for example, "C 3-12 "Cycloalkyloxy" refers to a cycloalkyloxy group containing 3 to 12 carbon atoms. 3-6 The term "cycloalkyloxy" refers to cycloalkyloxy groups containing 3 to 6 carbon atoms, including but not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0167] "Cycloalkoxy" or "cycloalkyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0168] "Heterocyclyloxy" or "heterocyclyloxy" refers to an -O-heterocyclyl group wherein heterocyclyl is as defined above and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azopentyloxy, nitrogen, oxhexyloxy, and the like.
[0169] "Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent.
[0170] “C 1-10 "Alkanoyl" refers to C 1-10 The monovalent atomic group remaining after removing the hydroxyl group from the alkyl acid is usually expressed as "C 0-9"C1 alkyl-C(O)-" refers to acetyl; "C2 alkyl-C(O)-" refers to propionyl; "C3 alkyl-C(O)-" refers to butyryl or isobutyryl.
[0171] "-C 0-8 Alkyl-OS(O)2R9" refers to the oxygen atom in -OS(O)2R9 attached to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0172] "-C 0-8 Alkyl-S(O) r R9" refers to -S(O) r The sulfur atom in R9 is connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0173] "-C 0-8 Alkyl-OR 10 " refers to -OR 10 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0174] "-C 0-8 Alkyl-C(O)OR 10 " refers to -C(O)OR 10 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0175] "-C 0-8 Alkyl-C(O)SR 10 ” refers to -C(O)SR 10 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0176] "-C 0-8 Alkyl-SC(O)R 11 ” refers to -SC(O)R 11 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0177] "-C 0-8 Alkyl-C(O)R 11 ” refers to -C(O)R 11 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8The alkyl group is as defined above.
[0178] "-C 0-8 Alkyl-OC(O)R 11 ” refers to -OC(O)R 11 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0179] "-C 0-8 Alkyl-P(O)(R 11 )2” refers to -P(O)(R 11 )2 in which the phosphorus atom is connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0180] "-C 0-8 Alkyl-NR 12 R 13 ” refers to -NR 12 R 13 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0181] "-C 0-8 Alkyl-C(O)NR 12 R 13 ” refers to -C(O)NR 12 R 13 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0182] "-C 0-8 Alkyl-N(R 12 )-C(O)R 11 ” refers to -N(R 12 )-C(O)R 11 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0183] "Halogen-substituted C 1-10 The term "alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl and tribromomethyl.
[0184] "Halogen-substituted C 1-10"Alkoxy" refers to an alkoxy group of 1-10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms. It includes but is not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.
[0185] "Deuterium replaces C 1-10 "Alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by deuterium atoms, including but not limited to monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, etc.
[0186] “Halogen” refers to fluorine, chlorine, bromine or iodine, “EA” refers to ethanol, “PE” refers to petroleum ether, “EtOAc” refers to ethyl acetate, “MeOH” refers to methanol, “DCM” refers to dichloromethane, and “DMSO” refers to dimethyl sulfoxide.
[0187] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, i.e., includes both substituted and unsubstituted instances. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group.
[0188] "Substituted" means that one or more "hydrogen atoms" in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, consistent with chemical valence theory, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated bonds (such as olefins).
[0189] "Stereoisomers," whose English name is stereoisomer, refer to isomers resulting from the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by rotation about single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds or rings in the molecule are called configuration stereoisomers, which are further divided into two categories. Among them, isomers caused by the inability to rotate freely around double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotation properties due to the lack of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations. In this invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.
[0190] "Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.
[0191] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0192] The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.
[0193] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 / 500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.
[0194] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. HPLC was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
[0195] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0196] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.
[0197] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures expressed in degrees Celsius (°C).
[0198] Ⅰ. Preparation of intermediates
[0199] Intermediate 1: Preparation of 2-(1-methylpiperidin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole Step 1: Synthesis of 5-chloro-2-(1-methylpiperidin-4-yl)benzo[d]thiazole
[0200] 2-Amino-4-chlorobenzenethiol (3.00 g, 18.8 mmol), 1-methylpiperidine-4-carboxylic acid (2.69 g, 18.8 mmol), N,N-diisopropylethylamine (6.55 mL, 37.6 mmol), and 50% 1-propylphosphonic anhydride (12.0 g, 18.8 mmol) were dissolved in a 100 mL round-bottom flask. The atmosphere was purged with nitrogen three times and stirred at 100°C overnight. The reaction mixture was cooled to room temperature, the pH was adjusted to 9-10 with saturated sodium bicarbonate solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation to afford 5-chloro-2-(1-methylpiperidin-4-yl)benzo[d]thiazole (4.50 g, yield: 90%). MS m / z (ESI): 267 [M+H] + .
[0201] Step 2: Synthesis of 2-(1-methylpiperidin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole
[0202] 5-Chloro-2-(1-methylpiperidin-4-yl)benzo[d]thiazole (1.80 g, 6.75 mmol) and pinacol diboron (2.57 g, 10.12 mmol) were dissolved in dioxane (40 mL). Potassium acetate (1.66 g, 16.87 mmol), tricyclohexylphosphine (305 mg, 1.09 mmol), and bis(dibenzylideneacetone)palladium (313 mg, 0.54 mmol) were added. The atmosphere was purged with nitrogen three times and stirred at 105°C overnight. After completion of the reaction, the mixture was filtered, the filter cake was washed with ethyl acetate, and the filtrate was concentrated by rotary evaporation. The residue was separated by column chromatography to afford 2-(1-methylpiperidin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (1.93 g, yield: 80%). MS m / z(ESI):359[M+H] + .
[0203] Intermediates 2 to 6 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of Intermediate 1:
[0204] Intermediate 7: Preparation of 2-methyl-5-(4-methylpiperidin-2-yl)benzo[d]thiazole
[0205] Step 1: Synthesis of 4-methylpiperidin-2-one
[0206] 4-Methylpyridin-2(1H)-one (25.0 g, 0.23 mol) was dissolved in acetic acid (30 mL), and 10% palladium on carbon (4.88 g) was added. The reaction mixture was stirred at 70°C under a hydrogen atmosphere for 24 hours. After the reaction was completed, the mixture was filtered and the filtrate was directly concentrated by rotary evaporation to obtain crude 4-methylpiperidin-2-one (25.4 g). MS m / z (ESI): 114 [M+H] + .
[0207] Step 2: Synthesis of tert-butyl 4-methyl-2-oxopiperidine-1-carboxylate
[0208] 4-Methylpiperidin-2-one (23.0 g, 0.20 mol) was dissolved in tetrahydrofuran (30 mL), and di-tert-butyl dicarbonate (47.8 mL, 0.22 mol), 4-dimethylaminopyridine (4.97 g, 40.6 mmol), and triethylamine (28.2 mL, 0.20 mol) were added. The mixture was stirred at room temperature for 24 hours. The reaction solution was diluted with ethyl acetate and water, the layers were separated, and the organic phase was concentrated by rotary evaporation. The residue was purified by column chromatography to give tert-butyl 4-methyl-2-oxopiperidine-1-carboxylate (7.0 g, yield: 16%). MS m / z (ESI): 158 [M-56+H] + Step 3: Synthesis of tert-butyl 4-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate
[0209] Dissolve tert-butyl 4-methyl-2-oxopiperidine-1-carboxylate (1.00 g, 4.69 mmol) in dry tetrahydrofuran (40 mL), cool to -78°C, and slowly add a solution of potassium bis(trimethylsilyl)amide in tetrahydrofuran (6.1 mL, 6.10 mmol). After complete addition, continue stirring at -78°C for 1 hour. Add N-phenylbis(trifluoromethanesulfonyl)imide (2.177 g, 6.10 mmol), and continue stirring at -78°C for 2 hours. The reaction solution is diluted with ethyl acetate and water, separated, and the organic phase is concentrated by rotary evaporation. The residue is purified by column chromatography to yield tert-butyl 4-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate (900 mg, yield: 54%). MS m / z (ESI): 290 [M-56+H] + .
[0210] Step 4: Synthesis of tert-butyl 4-methyl-6-(2-methylbenzo[d]thiazol-5-yl)-3,4-dihydropyridine-1(2H)-carboxylate
[0211] Dissolve tert-butyl 4-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate (319 mg, 1.16 mmol) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (400 mg, 1.16 mmol) in dioxane (9 mL) and water (3 mL). Add sodium carbonate (368 mg, 3.48 mmol) and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (85 mg, 0.12 mmol). Replace the atmosphere with nitrogen three times and stir at 90°C overnight. After the reaction, dilute with water and extract twice with ethyl acetate. Combine the organic phases and concentrate by rotary evaporation. The residue was purified by column chromatography to give tert-butyl 4-methyl-6-(2-methylbenzo[d]thiazol-5-yl)-3,4-dihydropyridine-1(2H)-carboxylate (180 mg, yield: 45%). MS m / z (ESI): 345 [M+H] + .
[0212] Step 5: Synthesis of 2-methyl-5-(4-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole
[0213] Dissolve tert-butyl 4-methyl-6-(2-methylbenzo[d]thiazol-5-yl)-3,4-dihydropyridine-1(2H)-carboxylate (180 mg, 0.52 mmol) in dichloromethane (2 mL) and add trifluoroacetic acid (2 mL). Allow to react at room temperature for 1 hour. After completion of the reaction, concentrate and remove the solvent. The residue is diluted with dichloromethane, adjusted to pH 8-9 with saturated sodium carbonate solution, and extracted twice with dichloromethane. The organic phases are combined and concentrated by rotary evaporation to yield 2-methyl-5-(4-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole (127 mg, yield: 100%). MS m / z (ESI): 245 [M+H] + .
[0214] Step 6: Synthesis of 2-methyl-5-(5-methylpiperidin-2-yl)benzo[d]thiazole
[0215] 2-Methyl-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole (128 mg, 0.52 mmol) was dissolved in methanol (5 mL) and cooled in an ice bath. Sodium borohydride (53 mg, 1.57 mmol) was added and stirred in an ice bath for 1 hour. After the reaction, the solvent was removed by concentration. The residue was purified by column chromatography to afford 2-methyl-5-(5-methylpiperidin-2-yl)benzo[d]thiazole (95 mg, yield: 74%). MS m / z (ESI): 247 [M+H] + .
[0216] Intermediates 8 to 15 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of Intermediate 7:
[0217] Intermediate 16: Preparation of 3-(2-(1-methylpiperidin-4-yl)benzo[d]thiazol-5-yl)morpholine
[0218] Step 1: Synthesis of tert-butyl 5-((diphenoxyphosphoryl)oxy)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate
[0219] Dissolve tert-butyl 3-oxomorpholine-4-carboxylate (1.00 g, 4.97 mmol) in dry tetrahydrofuran (40 mL), cool to -40°C, and slowly add a solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (5.47 mL, 5.47 mmol). After the addition is complete, continue stirring at -40°C for 1 hour. Then, add diphenylphosphinochloridate (1.09 mL, 5.22 mmol), and continue stirring at -40°C for 2 hours. The reaction solution is diluted with ethyl acetate and saturated ammonium chloride solution. The layers are separated, and the organic phase is concentrated by rotary evaporation. The residue is separated by column chromatography to yield tert-butyl 5-((diphenoxyphosphoryl)oxy)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate (1550 mg, yield: 72%). MS m / z (ESI): 334 [M-Boc+H] + .
[0220] Step 2: Synthesis of tert-butyl 5-(2-methylbenzo[d]thiazol-5-yl)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate
[0221] Dissolve tert-butyl 5-((diphenoxyphosphoryl)oxy)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate (750 mg, 1.38 mmol) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (381 mg, 1.38 mmol) in dioxane (15 mL) and water (3 mL). Add sodium carbonate (587 mg, 5.54 mmol) and 1,1-bis(diphenylphosphino)diphenylferric palladium chloride (101 mg, 0.14 mmol). Replace the atmosphere with nitrogen three times and stir at 95°C overnight. After the reaction is complete, dilute with water and extract twice with ethyl acetate. Combine the organic phases and concentrate by rotary evaporation. The residue was separated by column chromatography to give tert-butyl 5-(2-methylbenzo[d]thiazol-5-yl)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate (400 mg, yield: 87%). MS m / z (ESI): 333 [M+H] + .
[0222] Step 3: Synthesis of 5-(2-methylbenzo[d]thiazol-5-yl)-3,6-dihydro-2H-1,4-oxazine
[0223] Tert-butyl 5-(2-methylbenzo[d]thiazol-5-yl)-2,3-dihydro-4H-1,4-oxazine-4-carboxylate (390 mg, 1.17 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (3 mL) was added. The mixture was allowed to react at room temperature for 3 hours. The reaction mixture was diluted with dichloromethane, the pH was adjusted to 8-9 with saturated sodium carbonate solution, and the mixture was extracted twice with dichloromethane. The organic phases were combined and concentrated by rotary evaporation to afford 5-(2-methylbenzo[d]thiazol-5-yl)-3,6-dihydro-2H-1,4-oxazine (270 mg, yield: 84%, purity: 85%). MS m / z (ESI): 233 [M+H] + .
[0224] Step 4: Synthesis of 3-(2-methylbenzo[d]thiazol-5-yl)morpholine
[0225] 5-(2-methylbenzo[d]thiazol-5-yl)-3,6-dihydro-2H-1,4-oxazine (270 mg, purity: 85%, 0.99 mmol) was dissolved in methanol (10 mL), sodium borohydride (100 mg, 2.97 mmol) was added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was concentrated and removed. The residue was purified by column chromatography to afford 3-(2-methylbenzo[d]thiazol-5-yl)morpholine (205 mg, yield: 86%). MS m / z (ESI): 235 [M+H] + .
[0226] Intermediates 17 to 19 can be prepared by selecting corresponding raw materials according to the synthetic method of intermediate 16 in whole or in part:
[0227] Intermediate 20: Preparation of 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid
[0228] Step 1: Synthesis of methyl 4-amino-5-bromo-2-fluorobenzoate
[0229] Methyl 4-amino-2-fluorobenzoate (20.8 g, 123.0 mmol) was dissolved in chloroform (500 mL). N-bromosuccinimide (21.89 g, 123.0 mmol) was added at 0°C and stirred at 20°C for 16 hours. The reaction solution was concentrated by rotary evaporation, and the crude product was separated by normal phase column chromatography to obtain methyl 4-amino-5-bromo-2-fluorobenzoate (27.9 g, yield 91%). MS m / z (ESI): 248, 250 [M+H] + .
[0230] 1 H NMR (400MHz, CDCl3) δ8.04 (d, J = 7.2Hz, 1H), 6.46 (d, J = 12.2Hz, 1H), 4.62 (s, 2H), 3.88 (s, 3H).
[0231] Step 2: Synthesis of methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
[0232] Methyl 4-amino-5-bromo-2-fluorobenzoate (27.9 g, 112.5 mmol) and pinacol diboronate (35 mL, 135 mmol) were dissolved in dioxane (300 mL). Potassium acetate (33.12 g, 337.4 mmol) and 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride (8.23 g, 11.2 mmol) were added. The mixture was stirred and reacted at 100°C for 18 hours. The reaction solution was filtered and dried by rotary evaporation. The crude product was diluted with water and extracted three times with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation. The crude product was separated by normal phase column chromatography to obtain methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (25.2 g, 76%). MS m / z(ESI):296[M+H] + .
[0233] 1H NMR (400MHz, CDCl3) δ8.25 (d, J = 9.2Hz, 1H), 6.24 (d, J = 13.2Hz, 1H), 5.29 (s, 2H), 3.86 (s, 3H), 1.34 (s, 12H).
[0234] Step 3: Synthesis of methyl 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylate
[0235] 5-Bromo-1-methyl-1H-pyrazole-4-carbonitrile (9.1 g, 48.9 mmol), methyl 4-amino-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (14.4 g, 48.9 mmol), potassium carbonate (27.04 g, 195.7 mmol), and tetrakis(triphenylphosphine)palladium (7.35 g, 6.4 mmol) were added to 1,4-dioxane (100 mL) and water (100 mL) and reacted at 100°C under nitrogen for 16 hours. The organic solvent was evaporated under reduced pressure, and the mixture was filtered. The filter cake was washed with ethanol (50 mL) and dried to obtain methyl 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (13.28 g, 99% yield). MS m / z(ESI):275[M+H] + .
[0236] Step 4: Synthesis of 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid
[0237] Methyl 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylate (13.28 g, 48.4 mmol) was added to tetrahydrofuran (100 mL) and water (100 mL), followed by the addition of lithium hydroxide monohydrate (4.06 g, 96.8 mmol) and allowed to react at 50°C for 16 hours. After completion of the reaction, the organic phase was dried, diluted with water, and extracted with ethyl acetate (200 mL x 6). The aqueous phase was adjusted to pH 2 with saturated potassium bisulfate, resulting in the precipitation of a large amount of solid. The filter cake was filtered and washed with water (100 mL) and acetonitrile (100 mL). After drying, the filter cake afforded 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid (6.7 g, 53% yield). MS m / z (ESI): 261 [M+H] + .
[0238] 1H NMR (400MHz, DMSO-d6) δ8.73(d,J=8.0Hz,1H),8.27(s,1H),7.54(s,2H),7.27(d,J=13.2Hz,1H),4.38(s,3H).
[0239] Intermediates 21-26 can be prepared by selecting corresponding raw materials according to the synthetic method of intermediate 20 in whole or in part:
[0240] Intermediate 27: Preparation of 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole
[0241] Step 1: Synthesis of methyl 4-methyl-5-oxopentanoate
[0242] In an ice-water bath, propionaldehyde (5.0 g, 86.09 mmol) was added to hexahydropyridine (14.66 g, 172.2 mmol) and potassium carbonate (4.76 g, 34.43 mmol). The mixture was stirred vigorously at room temperature for 18 hours. The mixture was filtered, the mother liquor dried over anhydrous sodium sulfate, and filtered again. The filtrate was concentrated and dissolved in acetonitrile (50 mL). Methyl acryloyl ester (14.82 g, 172.2 mmol) was slowly added dropwise. The reaction mixture was heated at reflux for 24 hours. Glacial acetic acid (10.34 g, 172.2 mmol) and water (50 mL) were added, and the mixture was refluxed for another 24 hours. The reaction mixture was diluted with water and extracted with tert-butyl methyl ether. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation. The crude product was separated by normal phase column chromatography to yield methyl 4-methyl-5-oxopentanoate (6.22 g, 47.6% yield).
[0243] 1 H NMR (400 MHz, CDCl3) δ 9.63 (d, J = 1.6 Hz, 1H), 3.68 (s, 3H), 2.48-2.40 (m, 1H), 2.41-2.35 (m, 2H), 2.10-2.02 (m, 1H), 1.71 (dq, J = 14.3, 7.3 Hz, 1H), 1.14 (d, J = 7.2 Hz, 3H). Step 2: Synthesis of (3R,8S)-8-methyl-3-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one
[0244] To a solution of methyl 4-methyl-5-oxopentanoate (6.222 g, 43.16 mmol) in toluene (100 mL) was added (R)-2-amino-2-phenylethan-1-ol (5.92 g, 43.16 mmol). The mixture was heated at reflux for 24 hours and dehydrated using a water separator. The reaction solution was concentrated, and the crude product was separated by normal phase column chromatography to afford (3R,8S)-8-methyl-3-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one (4.866 g, 46.3% yield). MS m / z (ESI): 232 [M+H] + .
[0245] 1 H NMR (400MHz, CDCl3) δ7.33-7.20(m,5H),4.93(dd,J=6.8,1.3Hz,1H),4.44(d,J=8.8Hz,1H),4.17-4.08(m,2H) ,4.01(dd,J=9.0,1.3Hz,1H),2.46-2.28(m,2H),2.02-1.87(m,2H),1.60-1.45(m,1H),1.21(d,J=6.4Hz,3H).
[0246] Step 3: Synthesis of (S)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylpiperidin-2-one
[0247] To a 200 mL solution of (3R,8S)-8-methyl-3-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one (4.866 g, 21.04 mmol) in anhydrous dichloromethane were added triethylsilane (7.34 g, 63.12 mmol) and titanium tetrachloride (17.96 g, 94.68 mmol). The mixture was reacted at 50°C for 24 hours. Additional triethylsilane (7.34 g, 63.12 mmol) and titanium tetrachloride (17.96 g, 94.68 mmol) were added, and the reaction was continued at 50°C for 24 hours. The reaction solution was slowly poured into a saturated sodium bicarbonate solution (500 mL). The aqueous phase was filtered and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by normal phase column to give (S)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylpiperidin-2-one (1.54 g, yield 31.4%). MS m / z (ESI): 234 [M+H] + .
[0248] Step 4: Synthesis of (S)-5-methyl-1-(1-phenylvinyl)piperidin-2-one
[0249] To a solution of (S)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylpiperidin-2-one (10.3 g, 44.15 mmol) in DMSO (150 mL) was added lithium hydroxide monohydrate (37.05 g, 882.9 mmol). The mixture was reacted at 135°C for 4 days. The mixture was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give (S)-5-methyl-1-(1-phenylvinyl)piperidin-2-one (7.383 g, 66.0% yield). MS m / z (ESI): 216.3 [M+H] + .
[0250] Step 5: Synthesis of (S)-5-methylpiperidin-2-one
[0251] To a solution of (S)-5-methyl-1-(1-phenylvinyl)piperidin-2-one (7.28 g, 33.81 mmol) in dichloromethane (30 mL) were added TFA (30 mL) and water (3 mL). The reaction was allowed to proceed overnight at 40°C. After concentration, the crude product was separated using a reverse phase column. After freeze-drying, ammonia (3 mL) was added, and the product was concentrated to dryness. The product was then slurried with ethyl acetate and filtered to give (S)-5-methylpiperidin-2-one (2.52 g, yield 62.6%). MS m / z (ESI): 114 [M+H] + .
[0252] 1 H NMR (400MHz, MeOD) δ3.30-3.24(m,1H),2.86(dd,J=12.2,10.1Hz,1H),2.39-2.26(m,2H),1.96-1.80(m,2H),1.54-1.40(m,1H),1.01(d,J=6.5Hz,3H).
[0253] Step 6: Synthesis of tert-butyl (S)-5-methyl-2-oxopiperidine-1-carboxylate
[0254] To a solution of (S)-5-methylpiperidin-2-one (2.02 g, 17.85 mmol) in tetrahydrofuran (25 mL) was added DMAP (327 mg, 2.68 mmol) and di-tert-butyl dicarbonate (6.22 g, 26.78 mmol). The reaction was allowed to react overnight at 25°C. The reaction solution was concentrated, diluted with dichloromethane, and washed with 5% potassium bisulfate solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give tert-butyl (S)-5-methyl-2-oxopiperidine-1-carboxylate (3.48 g, 12.55 mmol, 70.3%). MS m / z (ESI): 214 [M+H]+ .
[0255] 1 H NMR(400MHz, CDCl3) δ3.83-3.75(m,1H),3.11(dd,J=12.7,10.4Hz,1H),2.63-2.53(m,1H),2.53-2.41 (m,1H),2.01-1.93(m,1H),1.92-1.83(m,1H),1.53(s,9H),1.46-1.40(m,1H),1.04(d,J=6.6Hz,3H).
[0256] Step 7: Synthesis of tert-butyl (S)-3-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate
[0257] To a solution of tert-butyl (S)-5-methyl-2-oxopiperidine-1-carboxylate (1.00 g, 4.69 mmol) in anhydrous tetrahydrofuran (25 mL) was added sodium bis(trimethylsilyl)amide (3.52 mL, 7.03 mmol) at -78°C. The reaction mixture was allowed to react at this temperature for 1 hour. N-phenylbis(trifluoromethanesulfonimide) (2.18 g, 6.10 mmol) was then added. The reaction mixture was slowly heated and stirred at room temperature for 3.5 hours. The reaction mixture was diluted with ethyl acetate and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by normal phase column chromatography to obtain tert-butyl (S)-3-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate (1.05 g, 62.4% yield). MS m / z (ESI): 290 [M+H-56] + .
[0258] 1 H NMR (400MHz, CDCl3) δ5.25(t,J=3.8Hz,1H),3.87(dd,J=12.8,3.3Hz,1H),3.00(dd,J=12.7,9.1Hz ,1H),2.44-2.34(m,1H),1.98-1.88(m,1H),1.88-1.78(m,1H),1.49(s,9H),0.99(d,J=6.6Hz,3H).
[0259] Step 8: Synthesis of tert-butyl (S)-6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-carboxylate
[0260] Tert-butyl (S)-3-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate (1.39 g, 4.02 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (1.00 g, 3.83 mmol), sodium carbonate (1.01 g, 9.57 mmol), and 1,1'-bis(diphenylphosphinoferrocenepalladium dichloride) (140 mg, 0.191 mmol) were added to 1,4-dioxane (30 mL) and water (10 mL) and reacted at 90°C under nitrogen for 18 hours. The reaction solution was diluted with ethyl acetate and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by normal phase column to give tert-butyl (S)-6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-carboxylate (1.01 g, yield 74.9%). MS m / z (ESI): 331 [M+H] + .
[0261] Step 9: Synthesis of (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole
[0262] To a solution of tert-butyl (S)-6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-carboxylate (1.01 g, 3.05 mmol) in dichloromethane (9 mL) was added trifluoroacetic acid (3 mL, 2.68 mmol). The mixture was allowed to react overnight at 25°C. The reaction mixture was concentrated, diluted with water, adjusted to pH 8 with aqueous ammonia, and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to afford (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole (0.70 g, 91.7% yield). MS m / z (ESI): 231 [M+H] + .
[0263] Step 10: Synthesis of 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole
[0264] To a solution of (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole (0.70 g, 3.04 mmol) in methanol (5 mL) was added sodium borohydride (308 mg, 9.12 mmol) under ice-water bath. The reaction mixture was stirred at room temperature for 45 minutes. The reaction mixture was concentrated, diluted with water, adjusted to pH 8 with aqueous ammonia, and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole (0.69 g, 97.6% yield). MS m / z (ESI): 233 [M+H] + .
[0265] 1 H NMR (400MHz, CDCl3) δ8.98(s,1H),8.15(d,J=1.7Hz,1H),7.88(d,J=8.3Hz,1H),7.56(dd,J=8.3,1.7Hz,1H),3.78(dd,J=11.4,2.6 Hz,1H),3.22-3.13(m,1H),2.48(t,J=11.4Hz,1H),1.97-1.87(m,2H),1.86-1.68(m,2H),1.30-1.19(m,1H),0.92(d,J=6.6Hz,3H).
[0266] II. Preparation of Examples
[0267] Example 1: Preparation of (4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinolin-8-yl)(2-(2-(1-methylpiperidin-4-yl)benzo[d]thiazol-5-yl)piperidin-1-yl)methanone
[0268] 2-(1-Methylpiperidin-4-yl)-5-(piperidin-2-yl)benzo[d]thiazole (74 mg, 0.15 mmol) and 4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid (40 mg, 0.15 mmol) were dissolved in N,N-dimethylformamide (3 mL), and triethylamine (71 mg, 0.70 mmol) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (80 mg, 0.21 mmol) were added. The atmosphere was replaced with nitrogen three times and the mixture was stirred at room temperature overnight. The reaction mixture was directly separated by reverse phase separation to give (4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinolin-8-yl)(2-(2-(1-methylpiperidin-4-yl)benzo[d]thiazol-5-yl)piperidin-1-yl)methanone (13 mg, yield: 15%). MS m / z (ESI): 558 [M+H]+ .
[0269] 1 H NMR(400MHz,DMSO-d6)δ8.33-7.72(m,4H),7.49-7.35(m,2H),7.29(s,2H),6.09-5.08(m,1H),4.60-4.42(m,3H ),3.80-3.48(m,1H),3.17-2.58(m,6H),2.20(s,3H),2.10-2.00(m,4H),1.88-1.76(m,2H),1.70-1.40(m,4H).
[0270] The compound of Example 1 (940 mg, 1.69 mmol) obtained according to the above preparation method was subjected to chiral SFC preparative separation (column type: AS-H 4.6*100 mm, 5 um; mobile phase: methanol [0.2% ammonia (7 M in methanol)] / acetonitrile = 30%; flow rate: 3.0 mL / min; column temperature: 40°C; detection wavelength: 214 nm) to obtain Example 1-1 (411 mg peak 1, retention time: 1.391 min) and Example 1-2 ((448 mg, peak 2, retention time: 1.890 min).
[0271] Examples 2 to 87 can be prepared by selecting corresponding raw materials according to all or part of the synthesis methods of Examples 1, 1-1, and 1-2:
[0272] The NMR data of the compound prepared in the above example are as follows:
[0273] Biological test evaluation
[0274] 1. Human Colon Cancer HCT116 Cell Proliferation Inhibition Assay
[0275] 1. HCT 116 MTAP knockout and MTAP wild-type cells were plated in 96-well flat-bottom plates and cultured overnight at 37°C and 5% CO2 using McCoy's 5A medium containing 10% fetal bovine serum and 1% penicillin-streptomycin.
[0276] 2. On the second day, dissolve the compound in DMSO, dilute the compound with DMSO and culture medium in sequence and transfer to the cell plate. The final concentration of the compound is 10 μM, 4-fold dilution, 9 concentration gradients plus DMSO control.
[0277] 3. Remove cells that have not been treated with the compound and detect cell viability using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the kit instructions. Then place the cell plate on the EnVision Multilabel Reader to detect the luminescence signal.
[0278] 4. At the same time, the cell plates treated with the compounds were cultured at 37°C and 5% CO2 for 6 consecutive days.
[0279] 5. Then, use CellTiter-Glo to detect cell activity.
[0280] 6. Finally, the dose-response curve was drawn using the four-parameter dose-response curve module of GraphPad Prism v 9.2.0 software and the IC of proliferation inhibition was calculated. 50 (Unit: nM).
[0281] From the biological activity data of the compounds in the specific examples, it can be seen that the series of compounds of the present invention have a strong inhibitory effect on the proliferation of human colon cancer HCT116 MTAP knockout cells at the cellular level.
[0282] Pharmacokinetics in mice
[0283] 1. Research Objectives
[0284] The purpose of this study is to study the pharmacokinetic behavior of some compounds of the present invention. The administration methods are: single oral administration (PO) to ICR mice, with a dosage of 10 mg / kg.
[0285] 2. Experimental Plan
[0286] 2.1 Investigational Drugs
[0287] The compounds used in this test are from the specific examples of the present invention.
[0288] 2.2 Experimental animals
[0289] ICR mice male N=3 Original source: Shanghai Xipul-Bikai Laboratory Animal Co., Ltd.
[0290] 2.3 Drug preparation and administration
[0291] Weigh each compound and dissolve it in a solvent consisting of 20% PG, 10% Solutol HS15, and 70% pH 3 citrate buffer. Shake well and sonicate to obtain a colorless, clear solution or suspension. Administer orally to nine mice after an overnight fast at a dose of 10 mg / kg.
[0292] 2.4 Sample collection:
[0293] 1) Approximately 90 μL of blood was collected from the submandibular vein at each time point. Anticoagulated with sodium heparin, placed on ice, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 8000 rpm, 6 minutes, 2-8 degrees Celsius).
[0294] 2) Blood samples were collected at 1, 4, and 24 hours. The samples were stored in a refrigerator at -20 degrees Celsius.
[0295] 3) To 40 μL of plasma sample, add 160 μL of ice-cold acetonitrile containing internal standard, vortex for 3 minutes, and centrifuge at 11,000 rpm for 5 minutes.
[0296] 4) Take 100 μL of the supernatant and add it to 100 μL of water. Take 5 μL and inject it into LC / MS / MS for analysis.
[0297] Analysis of blood-brain barrier penetration in mice
[0298] Kp is calculated using the AUC or concentration in the brain or plasma measured by the above method. Kp refers to the relationship between drug concentrations in the brain and blood and is used to assess the drug's ability to penetrate the blood-brain barrier. Post-dose Kp is calculated using the following formula:
[0299] Kp = [AUC (brain) / AUC (plasma)], or, Kp = [drug concentration (brain) / drug concentration (plasma)].
[0300] Table 2: Kp data of example compounds and comparative compounds
[0301] From the above data, it can be seen that the compounds of Examples 82 and 83 of the present invention have very high Kp and excellent blood-brain barrier penetration properties.
[0302] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in, X1 is CR6 or N; X2 is CR7 or N; X3 is CR8 or N; Ring A is C 4-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; Ring B is selected from a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, wherein the nitrogen atom is connected to the carbonyl group, wherein 1) When ring B is selected from a 4-membered nitrogen-containing heterocyclic group, an 8-10-membered nitrogen-containing heterocyclic group or an 8-10-membered nitrogen-containing heteroaryl group, Ring C is C 3-12 Cycloalkyl, 4-12 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-12 Cycloalkyl or 4-12 membered heterocyclic group is optionally fused to C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 Aryl or 5-10 membered heteroaryl is optionally fused to C 3-12 Cycloalkyl or 4-12 membered heterocyclic group; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; 2) When ring B is selected from a 5-7 membered nitrogen-containing heterocyclic group or a 5-7 membered nitrogen-containing heteroaryl group, Ring C and -(R1) m Together they form: in, a) When ring C and -(R1) m Formed together When Y1 and Y2 are each independently CR1 or N, Y3 is O, S or NR1', and Y4 and Y5 are each independently CR1" or N; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R1' is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Each R1" is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; b) When ring C and -(R1) m Formed together When Y6, Y7, Y8 and Y9 are each independently CR1 or N, and at least one is selected from CR1, wherein at least one R1 is -C 0-8 Alkyl-NR 14 R 15 or -OC 1-4 Alkyl-NR 14 R 15 , each other R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 , or, when p ≥ 2, wherein two R2 together with the moiety to which they are directly attached form a C(O); R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyl and -NR 12 R 13 substituted by a substituent; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 alkyl -C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 ; Each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 10 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent, or R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent; R 14 and R 15 are each independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2 and -C 0-8 Alkyl-C(O)NR 12 R 13 , or, R 14 and R 15 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaromatic radical, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R9, -C 0-8 Alkyl-S(O) r R9, -C 0-8 Alkyl-OR 10 、-C 0-8 Alkyl-C(O)OR 10 、-C 0-8 Alkyl-C(O)SR 10 、-C 0-8 Alkyl-SC(O)R 11 、-C 0-8 Alkyl-C(O)R 11 、-C 0-8 Alkyl-OC(O)R 11 、-C 0-8 Alkyl-P(O)(R 11 )2. -C 0-8 Alkyl-NR 12 R 13 、-C 0-8 Alkyl-C(O)NR 12 R 13 and -C 0-8 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Each r is independently 0, 1, or 2; m is selected from 0, 1, 2, 3, 4 or 5; n is selected from 0, 1, 2, 3, 4 or 5; and p is selected from 0, 1, 2, 3, 4 or 5.
2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 12 R 13 substituted by a substituent; Among them, R 12 and R 13 As claimed in claim 1; Preferably, R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups.
3. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 ; Preferably, R6, R7 and R8 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
4. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 14 and R 15 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2 and -C 0-4 Alkyl-C(O)NR 12 R 13 , or, R 14 and R 15 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Preferably, R 14 and R 15 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -C(O)OR 10 、-C(O)SR 10 、-C(O)R 11 、-P(O)(R 11 )2 and -C(O)NR 12 R 13 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
5. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Preferably, each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
6. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 , or, when p ≥ 2, wherein two R2 together with the moiety to which they are directly attached form a C(O); Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
7. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring B is selected from a 4-membered nitrogen-containing heterocyclic group; Ring C is C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 3-6 Cycloalkyl or 4-8 membered heterocyclic group is optionally fused to C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is optionally fused to C 3-6 Cycloalkyl or 4-8 membered heterocyclic group; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
8. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring B is selected from 8-10 membered nitrogen-containing heterocyclic groups; Ring C is C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 3-6 Cycloalkyl or 4-8 membered heterocyclic group is optionally fused to C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is optionally fused to C 3-6 Cycloalkyl or 4-8 membered heterocyclic group; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
9. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring B is selected from a 5-7 membered nitrogen-containing heterocyclic group, and Ring C and -(R1) m Formed together wherein Y1 and Y2 are each independently CR1 or N, Y3 is O, S or NR1′, and Y4 and Y5 are each independently CR1″ or N; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; R1' is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)R 11 and -C(O)NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Each R1" is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、 -C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
10. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring B is selected from a 5-7 membered nitrogen-containing heterocyclic group, and Ring C and -(R1) m Formed together wherein Y6, Y7, Y8 and Y9 are each independently CR1 or N, and at least one is CR1, wherein at least one R1 is -C 0-4 Alkyl-NR 14 R 15 or -OC 1-4 Alkyl-NR 14 R 15 , each other R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R9, -C 0-4 Alkyl-S(O) r R9, -C 0-4 Alkyl-OR 10 、-C 0-4 Alkyl-C(O)OR 10 、-C 0-4 Alkyl-C(O)SR 10 、-C 0-4 Alkyl-SC(O)R 11 、-C 0-4 Alkyl-C(O)R 11 、-C 0-4 Alkyl-OC(O)R 11 、-C 0-4 Alkyl-P(O)(R 11 )2. -C 0-4 Alkyl-NR 12 R 13 、-C 0-4 Alkyl-C(O)NR 12 R 13 and -C 0-4 Alkyl-N(R 12 )-C(O)R 11 substituted by a substituent; Among them, R9, R 10 、R 11 、R 12 、R 13 、R 14 、R 15 and r as claimed in claim 1.
11. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R9 is independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 10 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 11 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 Heterocyclic oxy group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 12 R 13 substituted by a substituent; Each R 12 and R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 substituted with an alkanoyl substituent, or R 12 and R 13 Together with the nitrogen atom directly connected thereto, a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-8 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.
12. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring A and its directly connected parts together form the following structure: Wherein, X1 is CR6 or N; X2 is CR7 or N; Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Each R7 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
13. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following structure: wherein Y1 and Y2 are each independently CR1 or N, and Y3 is O, S or NR1′; Ring A is C 4-8 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl; Ring B and -(R2) p Together they form the following structure: Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、 -C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; R1' is selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R2 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ; R2' is selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 ; R6 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, hydroxyl and -NR 12 R 13 ; Among them, R9, R 10 、R 11 、R 12 、R 13 , n, p and r as described in claim 1.
14. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Ring A and its directly connected parts together form the following structure: Wherein, X1 is CR6 or N; X2 is CH or N; Each R 5a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R 5c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5 and -OR 10 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R9, -S(O) r R9, -OR 10 、-C(O)OR 10 、-C(O)SR 10 、-SC(O)R 11 、-C(O)R 11 、-OC(O)R 11 、-P(O)(R 11 )2、-NR 12 R 13 、-C(O)NR 12 R 13 and -N(R 12 )-C(O)R 11 substituted by a substituent; Each R6 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -OR 10 ; Among them, R9, R 10 、R 11 、R 12 、R 13 and r as claimed in claim 1.
15. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following compound structure: Wherein, the compound of formula (III1) or formula (III2) has the following structure: The structure is Ring A and its directly connected parts together form the following structure: R is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, dimethylamino-substituted methyl, dimethylamino-substituted ethyl, dimethylaminoethoxy, cyclopropyl, cyclobutyl, piperidinyl, piperazinyl, morpholinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, methyl-substituted piperazinyl, cyclopropyl-substituted piperazine, and tetrahydropyranyl; R1' is selected from hydrogen, deuterium, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, dimethylamino-substituted methyl, dimethylamino-substituted ethyl, cyclopropyl, cyclobutyl, piperidinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, and tetrahydropyranyl; Each R2 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, cyclopropyl, -SF5 and hydroxyl; Each R 5b are each independently selected from hydrogen, deuterium, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl and cyclopropyl; Each R 5c Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, cyclopropyl, -SF5 and hydroxyl; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, cyclopropyl, -SF5 and hydroxyl; p is selected from 0, 1 or 2.
16. The compound of formula (I) according to claim 15, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: In the structure of the compound of formula (III1) or formula (III2) The structure is Ring A and its directly connected parts together form the following structure: wherein R1 is selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuterium, methoxy, trifluoromethoxy, amino, methylamino, ethyl substituted with dimethylamino, ethoxy substituted with dimethylamino, cyclopropyl alkyl, piperidinyl, piperazinyl, morpholinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, methyl-substituted piperazinyl, cyclopropyl-substituted piperazine, and tetrahydropyranyl; Each R2 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5a are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5b are each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl; Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl.
17. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following compound structure: in, each R1 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, trifluoromethyl, trideuteriomethyl, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino-substituted ethyl, dimethylamino-substituted ethoxy, cyclopropyl, piperidinyl, piperazinyl, morpholinyl, methyl-substituted piperidinyl, ethyl-substituted piperidinyl, cyclopropyl-substituted piperidinyl, methyl-substituted piperazinyl, cyclopropyl-substituted piperazinyl, and tetrahydropyranyl; Each R 2a are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 2b are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5a are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R 5b are each independently selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl; Each R 5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl.
18. The compound of formula (I) according to any one of claims 1 to 17, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:
19. A method for preparing the compound of formula (I) according to claim 1, its stereoisomers, or pharmaceutically acceptable salts thereof, characterized in that: The method comprises the following steps: reacting a compound of formula (Ia) with a compound of formula (Ib) to generate a compound of formula (I), and the reaction formula is as follows: wherein X is hydroxy or halogen; and Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, X1, X2, X3, m, n and p are as described in claim 1.
20. A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 to 18, its stereoisomers or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
21. Use of the compound of formula (I) according to any one of claims 1 to 18, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a drug for treating MATP-related tumors.
22. The use according to claim 21, characterized in that The tumor is selected from the group consisting of cell tumors, lymphomas, leukemias, osteomas, malignant teratomas, intraepithelial carcinomas, adenomas, fibromas, melanomas, fallopian tube cancer, bladder cancer, teratomas, embryonal carcinomas, choriocarcinomas, lipomas, liver cancer, bile duct cancer, lung cancer, gastric cancer, hemangiomas, gallbladder cancer, ampullary cancer, malignant melanomas, nevi, dysplastic nevi, myeloproliferative diseases, Hodgkin's disease, chordomas, myxomas, rhabdomyomas, leiomyomas, hamartomas, mesotheliomas, insulinomas, glucagonomas, gastrinomas, carcinoid tumors, viper tumors, granulomas, xanthomas, osteitis deformans, ependymomas, neurilemmomas, congenital tumors, meningiomas, gliomas, skin cancers, head and neck cancers, and sarcomas.
23. The use according to claim 22, characterized in that The cell tumor is selected from the group consisting of granulosa-thecoma, Sertoli cell tumor, germ cell tumor, Wilms tumor, seminoma, hepatoblastoma, malignant fibrous histiocytoma, chondroblastoma, giant cell tumor, astrocytoma, medulloblastoma, glioblastoma multiforme, oligodendroglioma, retinoblastoma, squamous cell carcinoma, clear cell carcinoma, transitional cell carcinoma, interstitial cell carcinoma, and basal cell carcinoma; The lymphoma is selected from malignant lymphoma and non-Hodgkin's lymphoma; The leukemia is selected from acute and chronic myeloid leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia; The bone tumor is selected from osteochondroma, benign enchondroma, osteoid osteoma, enchondromatous hamartoma, multiple myeloma and skull tumor; The adenoma is selected from the group consisting of fibroadenoma, adenomatoid tumor, hepatocellular adenoma, bronchial adenoma, tubular adenoma, villous adenoma, breast cancer, pancreatic cancer, endometrial adenocarcinoma, prostate cancer, ductal adenocarcinoma and colorectal adenocarcinoma; The fibroma is selected from the group consisting of fibroma, chondromyxofibroma, neurofibroma and spinal neurofibroma; The myeloproliferative disease is selected from the group consisting of multiple myeloma and myelodysplastic syndrome; The lung cancer is selected from bronchogenic carcinoma and alveolar carcinoma; The sarcoma is selected from the group consisting of fibrosarcoma, botryoid sarcoma, angiosarcoma, Kaposi's sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, and meningeal sarcoma.
24. The compound of formula (I) according to any one of claims 1 to 18, its stereoisomer or a pharmaceutically acceptable salt thereof for use as a PRMT5 inhibitor.
